Skip to content
Beacon

THNRAmplify Weight Loss Drug & Treatment ETF

Grow my money2y track recordRanked #2,570 of 2,960 in this goal

Seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index.

By Amplify ETFs · Launched 2024

Annual Cost

0.59%

#3,001 of 5,562 · average

Fund Size

$4M

#5,140 of 5,562 · small

Return (1Y)Goal

+5.1%

Track Record

2 years

#3,578 of 5,562 · seasoned

Performance

Total-return NAV · USD
Growth of $10,000
$10,816+8.2%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Strategy

Index tracking

Sector

Health care

Focus

Obesity & GLP-1

Index tracked

VettaFi Weight Loss Drug & Treatment Index

What it actually holds

By weight

Concentration

Top 10 holdings = 69.4% of fundconcentrated

Eli Lilly & Co
13.1%
Novo Nordisk A/S
12.5%
Regeneron Pharmaceuticals Inc
6.8%
Amgen Inc
6.8%
Chugai Pharmaceutical Co Ltd
6.5%
Shionogi & Co Ltd
4.8%
Pfizer Inc
4.8%
AbbVie Inc
4.7%
Roche Holding AG
4.7%
AstraZeneca PLC
4.7%

Asset allocation

Stocks
98.8%
Cash
0.9%
Other
0.3%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
19.2%Moderate

Year-on-year price swings

Max drawdown
-32.5%Severe

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Where to buy

Listing

Exchange
NYSE Arca

Full fund details

Objective
Seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index.
Strategy
Invests primarily in securities that comprise the Index, using a replication strategy to achieve its objective. May also use representative sampling to invest in a sample of securities whose characteristics closely resemble those of the Index as a whole.
Inception date
May 20, 2024
Fund family
Amplify ETFs

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Thematic
Warning

Thematic ETF — launched after the rally

Thematic funds are typically launched after a theme has delivered its strong returns. Morningstar's 2024 Global Thematic Funds Landscape finds that only about 1 in 10 thematic funds have survived and beaten a broad global equity benchmark over the past 15 years — roughly 60% have been closed outright. The narrative is always compelling; the track record rarely is.

Source: Morningstar, 'Global Thematic Funds Landscape' (2024)

Why we flagged this: Narrow thematic name, launched in the last 3 years, $4M in assets (under our $500M threshold).

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've reviewed THNR. Save it to your watchlist to track it alongside the other funds you're weighing.

Data updated on 2026-06-19